Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma
Marcelo C. Pasquini(Cleveland Clinic), Edmund K. Waller(Emory University), Jennifer Le Rademacher(Medical College of Wisconsin), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Kazunobu Kato(Otsuka (United States)), Ira Braunschweig(The University of Texas MD Anderson Cancer Center), Vijay Reddy(University of Florida), Damiano Rondelli(University of Illinois Chicago), James R. Mason(Sheba Medical Center), César O. Freytes(CHRISTUS Transplant Institute), Elizabeth Armstrong(Otsuka (United States)), Agnes Elekes(Otsuka (United States)), Weiyun Z. Ai(City College of San Francisco), Jeanette Carreras(Medical College of Wisconsin), Shin Mineishi(University of Alabama at Birmingham), Tsiporah B. Shore(Cornell University), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Michael Craig(Edith Cowan University), Cathy Zhao(Otsuka (United States)), Angela Smith(Otsuka (United States)), Thomas C. Shea(University of North Carolina at Chapel Hill), Joseph W. Fay(Sheba Medical Center), Michael Lill(Cedars-Sinai Medical Center), William P. Vaughan(University of Pennsylvania Health System), Luciano J. Costa(University of Alabama at Birmingham)
Cited by 5
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k